Cannabis
AgraFlora Organics Enters 2020 with Fully Automated Industrial Scale Edibles Facility, 2.2m Sq. Ft. Production Facility, Worldwide Distribution and Brands
VANCOUVER, British Columbia, Jan. 07, 2020 (GLOBE NEWSWIRE) — AgraFlora Organics International Inc. (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF), a growth oriented and diversified international cannabis company, is pleased to provide the following corporate review of the calendar year 2019.
2019 Year In Review
2019 was a transformative year for AgraFlora, bookended by accretive acquisitions and commercial arrangements for the Company, including the increase of AgraFlora’s equity stake to 70 per-cent in its Propagation Services Canada (“PSC”) joint venture. PSC houses the Company’s 2.2 million square foot Delta Greenhouse Facility; second in size and magnitude only to the Smiths Falls facility owned by Canopy Growth Corporation, the world’s largest cannabis company. The Delta Greenhouse Facility is a state-of-the-art pressurized, semi-open Venlo greenhouse, which is widely considered to be one of the most technically advanced and environmentally friendly greenhouse operations in the world.
Additionally, the Company completed a watershed acquisition of a portfolio of cannabis 2.0 assets from an arms-length party, underpinned by a 51,500 square foot GMP-certified Winnipeg Edibles Manufacturing Facility (the “Winnipeg Edibles Facility”). Furthermore in 2019, AgraFlora aggregated the following high-margin cannabis 2.0 and downstream assets, infrastructure and brands:
AgraFlora’s upstream and downstream operating portfolio affords the Company unmatched cannabis 2.0 optionality as the industry continues to mature.
Brandon Boddy, Chairman and Chief Executive Officer of AgraFlora stated: “2019 was a transformational year for AgraFlora and one that saw the Company evolve from a domestic cultivator to a vertically integrated, international cannabis company. Our world-class Delta Greenhouse Facility will catapult us into the ranks as a top five Canadian Licensed Producer, and when coupled with our scalable, cannabis 2.0 manufacturing capabilities equips us with a opportunity to leverage our existing asset portfolio and licensed infrastructure to generate high-margin cash flows, while capture defendable market share. As we begin to execute on our profit-focused 2020 blueprint, we continue to receive unrivalled support from our best in class joint-venture partners and industry consultants. AgraFlora boasts the human capital necessary to succeed in a dynamic cannabis industry, including corporate partners with centuries of experience in their respective domains: the Houwelings Group and our Edibles Manufacturing cohort. We anticipate another pivotal year in 2020, as all facilities reach full production capacity, and our products continue to penetrate the legal cannabis market across both domestic and international marketplaces.”
Flagship Production and Manufacturing Assets
AgraFlora’s cannabis manufacturing stratagem is led by its 51,500 square foot, GMP Winnipeg Edibles Facility. To the Company’s knowledge, its Winnipeg Edibles Facility is the only industrial-scale edibles facility in the country to boast complete automation and production mechanizations, as opposed to the hand manufacturing processes employed by its Tier 1 licensed producer peers. AgraFlora’s Winnipeg Edibles Facility is outfitted with fully automated production flows; therefore, reducing associated labour costs and optimizing product throughput, as follows:
The Company’s Winnipeg Edibles Facility, with 51,500 square feet, is equipped with over 30,000 square feet of dedicated edibles production space, as well as a 750-square-foot pharmaceutical-grade edibles research laboratory. Once activated, the Winnipeg Edibles Facility will be operated by a roster of third generation chocolatiers/confectioners and boasts state-of-the-art manufacturing equipment capable of producing an assortment of both cannabinoid/terpene-infused products for medicinal, functional and adult use.
AgraFlora’s bellwether production hub, the Delta Greenhouse Facility is a state-of-the-art pressurized, semi-open Venlo greenhouse, which is widely considered to be one of the most technically advanced and environmentally friendly greenhouse operations in the world. Upon successful award of its aforementioned Health Canada cultivation licence, the Delta Greenhouse Facility will hold claim to the highly coveted spot as the world’s second-largest cannabis cultivation operation under glass, with an estimated replacement cost of $190 million.
By way of additional comparison, AgraFlora’s Delta Greenhouse Facility is 100,000 square feet larger than Aurora Cannabis Inc.’s facility in Edmonton, Alberta, and it is also more than 700,000 square feet larger than the current size of the Leamington facility owned by Aphria Inc. AgraFlora’s internal forecasts indicate that upon receipt of its aforementioned standard cultivation licence from Health Canada, the company will become the fourth-largest licensed producer (LP) in Canada by 2020 financed production metrics:
The Company plans to pursue the processing of EU-GMP compliant cannabis products from its flagship 2.2 million square foot Delta Greenhouse Facility for integration into its European distribution channels. EU-GMP certified cannabis products are eligible for import/export and sale in the European Union.
Cannabis 2.0
In preparation for the next phase of cannabis normalization, as well as the associated regulations, AgraFlora has executed on an assertive corporate acquisition stratagem, amassing a diverse portfolio of vertically integrated cannabis 2.0 assets and industry partnerships, focused on the following mandates:
Throughout 2019, the Company by way of direct capital disbursement and/or acquisition deployed over $85 million in associated plant, property and equipment (“PPE”) expenditures related to its cannabis 2.0 asset portfolio. Highlights of AgraFlora’s cannabis 2.0 PPE expenditures are as follows:
Health Canada Licensing
The Company and its associated subsidiaries were awarded the following Health Canada licenses in the year 2019: The aforementioned Health Canada licenses function as a foundation for AgraFlora’s anticipated award of a standard cultivation license at its 2.2 million square foot Delta Greenhouse Facility. In September 2019, AgraFlora submitted its affirmation of readiness and video evidence package to Health Canada for its Phase 1 build out at the Delta Greenhouse Facility. To date, the Company has received two separate rounds of request-for-more-information (the “RMIs”) and reports no material deficiencies in its application. AgraFlora plans to submit its second RMI response to Health Canada on or before January 15, 2020. The Company remains confident its upcoming RMI response will address all outstanding requests from Health Canada.
In December of 2019, AgraFlora entered into an interim agreement to acquire 100 per-cent of Sanna Health Corp., a Canadian cannabis company based in the Greater Toronto Area. Sanna’s flagship asset is the Sustainable Growth Strategic Facility which is situated on 16 acres and includes 27,000 square feet of Health Canada licensed cultivation and processing space. Coupled with an option to expand its current production area to 89,000 square feet as well as ample commercial-industrial space for future expansion. Once Ontario’s anticipated regulatory changes take effect expanding retail opportunities Sanna will look to architect and operate an on-site dispensary allowing the Company to capitalize on its prime proximity to the seven million population in the GTA and immediately surrounding areas.
Construction
Throughout 2019, AgraFlora completed 99 per-cent of its Phase 1 facility retrofit and construction initiatives at the Delta Greenhouse Facility, including:
The Phase 1 retrofit at the Company’s flagship Delta Greenhouse Facility comprises approximately 431,000 square feet of cultivation/processing expanse, including over 130,000 square feet of net flower canopy and is estimated to produce 15 million grams of premium cannabis annually.
AgraFlora also reports substantial progress pertaining to retrofit and construction initiatives at its Winnipeg Edibles Facility during the 2019 calendar year. The Company forecasts construction will be completed at its Winnipeg Edibles Facility during the first quarter of 2020.
During Q4 2019, AgraFlora also announced the commencement of a retrofit to seven of the non-core operating buildings at its New Brunswick cannabis campus, including: European Distribution
The fourth quarter of 2019 saw AgraFlora acquire 100 per-cent of the issued and outstanding shares of The Good Company GmbH (“The Good Company”), with The Good Company becoming a wholly-owned subsidiary of AgraFlora. The Good Company is the parent company of German European Union good distribution practice medical cannabis distributor (EU-GDP) Farmako GmbH (“Farmako”). Farmako is a leading European medical cannabis distributor, headquartered in Frankfurt, Germany, with affiliated companies in the United Kingdom, Luxembourg and Denmark.
This acquisition expedited AgraFlora’s entrance into the European cannabis theatre by arming the Company with existing cannabis distribution infrastructure, supply and licenses/certifications, all while equipping the Company with experienced European cannabis operators. The combined AgraFlora-Farmako entity will function as a high-margin European distribution hub for the Company’s medical cannabis flower and EU-GMP certified manufactured cannabis products produced from its Delta Greenhouse Facility, AAA Heidelberg craft cannabis facility and 27,000 square foot Scarborough, Ontario cultivation and processing facility.
Farmako realized revenues of over $2.75 million throughout the 2019 fiscal year and has succeeded in capturing an 8 per-cent market share of Germany’s burgeoning medical cannabis arena, while maintaining the highest capital efficiency and positive EBIT margins within the industry.
Domestic Distribution
AgraFlora currently has memorandums of understanding (MoUs) in place with established cannabis retailers, Canna Cabana by High Tide Inc (“Canna Cabana”)., as well as Delta 9 Cannabis Inc. (“Delta 9”). In aggregate, Canna Cabana and Delta 9 will boast 45 licensed, high-traffic brick-and-mortar retail locations across Canada by the first quarter of 2020. In Q4 of 2019, AgraFlora achieved approved supplier status from Gateway Newstands (“Gateway”), North America’s premier newsstand retailer, thus securing high-visibility Canadian shelf space for the Company’s CPG product offering across Gateway locations. AgraFlora and Gateway also announced the companies will also deploy best commercial efforts to pursue conversations relating to a CBD supply and consulting agreement, whereby AgraFlora and Gateway may collaborate to produce a portfolio of CBD-infused CPGs, within eligible jurisdictions.
Asia Pacific Distribution
In Q3 of 2019, the Company entered into a definitive agreement to acquire 50 per-cent of the issued and outstanding shares of Eurasia Infused Cosmetics Inc. AgraFlora and Eurasia will collaborate to integrate the company’s vertically integrated, farm-to-face CBD processing, manufacturing and distribution model into the Asia Pacific region.
Eurasia Infused, by way of a commercial concession with CBD Group Asia Ltd., controls distribution agreements for CBD and organic cannabis sativa seed oil consumer packaged goods (“CPGs”) for the territories of the People’s Republic of China, as well as the Hong Kong special administrative region. This distribution agreement extends to AgraFlora’s existing portfolio of CBD-infused and organic cannabis sativa seed oil derived product suite.
$30 Million Financing In December of 2019, AgraFlora closed its previously announced private placement of convertible debentures (the “Offering”) for gross proceeds of $30 million.
Each Debenture consists of one senior unsecured convertible debenture (each, a “Debenture”) of the Company in the principal amount of $1,000. Each Debenture is convertible, in whole or in part at the right of the holder, into: (i) that number of common shares in the capital of the Company (the “Debenture Shares”) that is equal to the principal amount of each Debenture being so converted divided by $0.30 per Debenture Share, subject to customary adjustment provisions in certain stated circumstances; and (ii) a cash payment equal to an amount corresponding to the interest that such holder would have received if it had held the Debenture from the date of conversion of such Debenture until March 12, 2021 (the “Maturity Date”). Upon conversion of the Debentures, the holder shall receive a cash payment equal to the accrued and unpaid interest due on the Debentures being so converted on and including the date of conversion. The Debentures will bear interest at a rate of 10.0 per-cent per annum, payable semi-annually, until the Maturity Date.
About AgraFlora Organics International Inc.
AgraFlora Organics International Inc. is a growth oriented and diversified company focused on the international cannabis industry. It owns an indoor cultivation operation in London, ON and is a joint venture partner in Propagation Services Canada Inc. and its large-scale 2,200,000 sq. ft. greenhouse complex in Delta, BC. The Company is also retrofitting a 51,500-square-foot good manufacturing practice (“GMP”) edibles manufacturing facility in Winnipeg, Manitoba. AgraFlora has a successful record of creating shareholder value and is actively pursuing other opportunities within the cannabis industry. For more information please visit: www.agraflora.com.
ON BEHALF OF THE BOARD OF DIRECTORS Brandon Boddy AgraFlora Organics International Inc. For French inquiries: The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the business plans for AgraFlora Organics described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com.
_______________________________
1 Forecasted fully funded production metrics derived upon achievement of optimized production at AAA Heidelberg and the Delta Greenhouse Complex. 
Issuer
2020 Estimated Annual Capacity (in grams)
Current Market Capitalization
Aurora
700,000,000
$2,680,203,000
Canopy Growth
525,000,000
$9,069,607,000
Aphria
255,000,000
$1,559,658,000
AgraFlora & PSC
251,250,0001
$79,417,000
Tilray
225,000,000
$1,286,841,000
Cronos Group
150,000,000
$3,076,257,000
OrganiGram
113,000,000
$437,302,000
Chairman & CEO
T: (604) 398-3147
For additional information:
Tim McNulty
E: [email protected]
T: (800) 783-6056
Remy Scalabrini, Maricom Inc.
E: [email protected]
T: (888) 585-MARI
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company’s board of directors (the “Board“) effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company’s commitment to driving growth while focusing on sustainable profitability.
“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”
Mr. Arbel retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.
“I am honored to join the Board of Directors at IMCC,” said Mr. Arbel. “I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”
Arbel holds a BA and MBA from Tel Aviv University.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the stated benefits Mr. Arbel’s appointment, including the further strengthening the Company’s commitment to driving growth in the German market while focusing on sustainable profitability; and Mr. Arbel’s international experience and track record in banking and finance will be invaluable to the Company.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance becoming invaluable to the Company.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance not becoming valuable to the Company.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
[email protected]
Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-302244961.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
-
Indivior1 week agoIndivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
-
Cannabis3 days ago
One World Products Issues Shareholder Update Letter
-
Cannabis3 days agoIM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors
